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(PD-1) inhibitors are now the pillars of a modern and effective 
treatment (figs. 1 and 2). They have replaced the use of chemother-
apy with dacarbazine and other cytotoxic agents in clinical prac-
tice. Further improvements could well be achieved by combining 
therapies that are presently available. In this review article, we 
summarize the current trials and the state-of-the-art systemic ther-
apies for advanced melanoma.
Targeted Therapy with Kinase Inhibitors (BRAF and 
MEK Inhibitors)
If the oncogene BRAF harbors activating mutations such as 
Val600Glu (V600E) or Val600Lys (V600K), targeted therapy with 
tyrosine kinase-inhibiting substances should be considered in the 
first- or second-line treatment. Several phase III studies indicate, in 
a very impressive way, that an upfront combination therapy with 
inhibitors to BRAF (BRAFi) and MEK (MEKi) is superior to 
BRAFi monotherapy alone (table 1).
Dabrafenib and Trametinib
The double-blind, randomized phase III study COMBI-d com-
pared dabrafenib and trametinib to dabrafenib alone. In a primary 
analysis after a median follow-up of 9  months, the combination 
was superior to monotherapy with a progression-free survival 
(PFS) of 9.3 and 8.8 months, respectively, and a hazard ratio (HR) 
for progression or death of 0.75 (95% confidence interval (CI) 
0.57–0.99). The objective response rate (ORR) lay at 67% for the 
combination and at 51% for the monotherapy cohort [1]. A final 
report on overall survival (OS) was performed when 70% of the 
intention-to-treat population had died [2]. The median OS was 
25.1  months in the dabrafenib plus trametinib group versus 
18.7 months in the dabrafenib only group (HR 0.71; 95% CI 0.55–
0.92). In the group treated with the combination, 74% and 51% of 
the patients survived the first and second year under observation. 
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Summary
Melanoma is a common type of skin cancer with a high 
propensity to metastasize. Tyrosine kinase inhibitors tar-
geting the mitogen-activated protein kinase (MAPK) 
pathway and immune checkpoint blockade have recently 
revolutionized the management of unresectable and 
metastatic disease. However, acquired resistance and 
primary non-response to therapy require novel treat-
ment strategies and combinations. The purpose of this 
review is to provide a brief and up-to-date overview on 
the clinical management and current trial landscape in 
melanoma. We summarize the most pertinent studies on 
BRAF/MEK inhibitors and blockade of cytotoxic T-lym-
phocyte-associated protein 4 (CTLA-4) and programmed 
cell death protein 1 (PD-1). Although most agents show 
robust antitumor efficacy as single agents, further im-
provements  have been achieved by the combination of 
both approved and developing drugs. We discuss ongo-
ing trials and evaluate future approaches that may pro-
vide additional efficacy with less toxicity.
© 2016 S. Karger GmbH, Freiburg
Introduction
In the last few years, the therapy for advanced melanoma has 
been revolutionized by introducing a panel of novel local and sys-
temic treatment approaches. In particular, targeted BRAF muta-
tion status-based therapies with tyrosine kinase inhibitors and im-
mune therapy with ipilimumab or programmed cell death protein 1 
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The PFS in the combination arm increased further to 11.0 months 
(HR 0.67; 95% CI 0.53–0.84). The response rates were 69% and 
53%, respectively [2]. In addition to objective clinical benefits such 
as delayed progression or longer OS, patients receiving the combi-
nation showed a better health-related quality of life along with sig-
nificant functional and pain improvements compared with patients 
receiving monotherapy with dabrafenib. However, some dimen-
sions of the questionnaires such as nausea and vomiting or diar-
rhea showed a trend of being favorable with dabrafenib only [3]. 
Recently, a 3-year analysis was presented (with a cut-off date for 
data of 15 February 2016), revealing a PFS of 22% (dabrafenib plus 
trametinib) versus 12% (dabrafenib only) and OS of 44% versus 
32%. The outcome was best in patients with normal serum lactate 
dehydrogenase (LDH) and less than 3 affected organ systems at 
baseline [4]. These data provide the so far longest follow-up on OS 
in patients receiving BRAFi and MEKi in a phase III trial setting.
The open-label, randomized phase III trial COMBI-v compared 
dabrafenib and trametinib to vemurafenib as first-line therapy in 
704 patients with metastatic melanoma with OS as primary end-
point [5]. The study was prematurely stopped for efficacy based on 
a positive interim analysis. Median OS was 17.2 months for the ve-
murafenib only group and was not reached by patients who were 
treated with the combination. The survival benefit was evident in 
all specified subgroups except for patients with an Eastern Coop-
erative Oncology Group (ECOG) score of 1 at baseline. Median 
Fig. 1. The mitogen-activated protein kinase (MAPK)-signaling pathway can 
be induced by activating mutations of receptor tyrosine kinases and mediated 
through the small guanosine triphosphate (GTP)ase NRAS, the serine/threo-
nine kinase BRAF and the MAPK kinases MEK and ERK. Specific BRAF in-
activation can be achieved with the inhibitors vemurafenib and dabrafenib, 
while cobimetinib, trametinib, and binimetinib block MEK kinase activity. 
These inhibitors have been approved in single and combination therapy by the 
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with an unfavorable prognosis, the survival time was significantly 
better. On the other hand, for the expression of other molecular 
tumor features, such as the proliferation marker Ki-67 or the tu-
mor-suppressors PTEN, no difference was detected with respect to 
the OS rate.
Similar results were reported for BRIM7 after an extended fol-
low-up. BRIM7 was initially designed as a dose-escalating phase Ib 
trial, which formed the basis for the development of the vemu-
rafenib and cobimetinib combination regimen [9]. Included study 
patients had either previously progressed on vemurafenib or were 
BRAFi naïve. A striking confirmed response rate of 87% was ob-
served in the latter group with 4 more patients attaining a complete 
response at cycles 16–25. The median PFS was left unchanged at 
13.8 months and the median OS was reached at 28.5 months. After 
2  years of follow-up, 61% of patients receiving vemurafenib and 
cobimetinib were still alive [10].
Binimetinib (MEK162)
Activating mutations of the oncogene NRAS are present in ap-
proximately 20% of patients with melanoma. Some studies pro-
posed that the NRAS mutation status is an independent predictor 
of short survival in stage IV disease [11]. Thus, NRAS-mutated pa-
tients are at high risk for disease progression and represent a popu-
lation with unmet clinical need, in particular after immune check-
point blockade has failed. Preclinical studies have shown that 
NRAS-mutated melanoma is sensitive to MEK inhibition [12, 13]. 
Binimetinib (MEK162), an oral inhibitor of both MEK1 and 
MEK2, was the first targeted therapy to show antitumor activity in 
patients with NRAS-mutated melanoma in a phase II trial [14]. 
This was the rationale for the NEMO trial to test binimetinib in a 
phase III setting in NRASQ61-mutated melanoma. Patients were 
randomized at a 2: 1 ratio to either binimetinib or dacarbazine. Bin-
imetinib significantly improved PFS over dacarbazine with a me-
Fig. 2. Blocking cytotoxic T-lymphocyte-associ-
ated protein 4 (CTLA-4) or programmed cell death 
protein 1 (PD-1) signaling in tumor immunother-
apy. T cells recognize antigens that are presented 
by dendritic cells (DC) or melanoma cells through 
the major histocompatibility complex (MHC) with 
their T-cell  receptors (TCR). Several signals regu-
late T-cell activity. They can be activated through 
costimulatory B7 molecules binding to CD28, 
while binding of B7 to CTLA-4 triggers inhibitory 
signals during the priming phase in lymph nodes. 
Binding of programmed death ligand 1 (PD-L1) on 
melanoma cells to PD-1 on T cells results in nega-
tive regulation during the effector phase in the 
 peripheral tissue. Thus, T-cell activation can be 
achieved by antibody-mediated blocking of 
CTLA-4 with ipilimumab or PD-1 with nivolumab 
or pembrolizumab. Years in which these antibodies 
have been approved for melanoma therapy by the 
EMA are depicted in the pillar.
PFS was 11.4 versus 7.3 months (HR 0.56; 95% CI 0.46–0.69) with 
best overall response rates of 64% and 51%, respectively [5]. Analo-
gous to COMBI-d, scores for global health and most functional 
and disease symptoms showed significant improvements in favor 
of the combination, further underlining that the upfront combina-
tion of BRAFi and MEKi is the standard of care for patients with 
activating BRAFV600 mutations [6].
Vemurafenib and Cobimetinib
The combination of vemurafenib and cobimetinib was ap-
proved by the European Medicines Agency (EMA) in December 
2015 based on the results of the pivotal coBRIM trial. Patients who 
had not previously been treated for unresectable or metastatic mel-
anoma received vemurafenib and cobimetinib or vemurafenib plus 
placebo with investigator-assessed PFS as primary endpoint [7]. 
The rate of complete or partial responses was 68% for the combi-
nation and 45% for the control group. After 9 months of follow-up, 
survival rates were 81% and 73%, respectively. The median PFS 
was 9.9 months in the combination group and 6.2 months for ve-
murafenib monotherapy [7]. After a median follow-up of 
14.2 months, PFS further increased to 12.3 and 7.2 months. Vemu-
rafenib plus cobimetinib showed a better ORR (70%) compared to 
that for vemurafenib plus placebo (50%). Of note, 16% of patients 
in the combination arm showed complete response. The duration 
of the response was 13.0 and 9.2 months, respectively. The treat-
ment-related benefits were consistent in every assessed patient sub-
group, including patients with BRAFV600E and BRAFV600K mu-
tations [8]. The survival data for the coBRIM were recently up-
dated after a median follow-up of 18.5 months. After 1 year, 75% of 
patients treated with the combination were alive. The 2-year sur-
vival rate was still 48%. Median OS amounted to 22.3 months for 
the combination as opposed to 17.4 months for vemurafenib only 
(HR 0.70; 95%CI 0.55–0.90). Even in patients with increased LDH 
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dian PFS of 2.8 versus 1.5  months (HR 0.62; 95% CI 0.47–0.80). 
The response rates in the intention-to-treat population were 15% 
and 7%, respectively. The median OS was not significantly im-
proved and lay at 11.0 months [4].
Safety and Tolerability
Although in the coBRIM study incidences of severe adverse 
events in the combination therapy were slightly elevated, other 
studies and the clinical practice have shown that the safety and the 
tolerability of both combinations are good. Cutaneous side effects 
such as the development of palmoplantar hyperkeratosis, squa-
mous cell carcinoma, or hair loss, which frequently occur under 
BRAFi monotherapy, are found less frequently with the combina-
tion due to simultaneous inhibition of MEK [2, 5]. However, nau-
sea, vomiting and diarrhea occur more frequently in the combina-
tion regimens. One of the most frequent adverse events of dab-
rafenib plus trametinib is pyrexia, which has been observed in 
more than 50% of all cases [1, 5]. On the other hand, with vemu-
rafenib plus cobimetinib, photosensitivity has been observed in 
20% of the cases [7]. Moreover, an important effect of MEKi is the 
reduction of the left ventricle ejection fraction, even to the extent 
of a clinically manifested heart insufficiency, as well as the develop-
ment of a  central serous retinopathy. Regular cardiac examina-
tions with electrocardiography and trans-thorax echocardiograms 
should be performed every 3 months as well as an examination of 
the retina with optical coherence tomography prior to treatment.
Immune checkpoint blockade
Ipilimumab Monotherapy
The antibody ipilimumab, which is directed against cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), is administered intra-
venously for 4 cycles at 3-weekly intervals, in contrast to the PD-1 
inhibitors, which are applied as continuous therapy. Pooled data 
from several phase ll and phase lll trials have recently been col-
lected and analyzed, revealing a median survival time of 
11.4 months for ipilimumab monotherapy [15]. Interestingly, the 
survival curves reach a plateau after 3 years and appear stable even 
10 years post treatment. According to the studies that have been 
published thus far, the response rates of ipilimumab as monother-
apy are lower than those with PD-1 inhibitors, and the rate of ad-
verse events is presumably higher. Events such as autoimmune co-
litis and hypophysitis may require hospitalization and result in ir-
reversible hormone deficiency. Thus, despite its proven long-term 
efficacy and the limited number of applications, the future of ipili-
mumab as monotherapy in melanoma is uncertain.
Pembrolizumab Monotherapy
Pembrolizumab is administered intravenously at 2 mg/kg body 
weight every 3 weeks and can be administered continuously over a 
period of at least 1–2 years if the response is favorable and the drug 
well tolerated. However, the optimal treatment duration has not 
been identified to date [16]. It was first evaluated in the large phase 
I KEYNOTE-001 study. After a median follow-up duration of 
18  months, the response rate was 34% and the median OS 
25.9 months. The responses were stable and maintained in 81% of 
patients, suggesting a high antitumor efficacy in the early stages of 
drug development [17]. The KEYNOTE-002 study compared 2 
dosage schemes of pembrolizumab in comparison to investigator-
choice chemotherapy (ICC) in patients who were refractory to ip-
ilimumab or to prior BRAFi. Both dosages of pembrolizumab, 
2 mg/kg and 10 mg/kg body weight, were clearly superior to ICC 
with respect to PFS and tolerability, providing the basis for acceler-
ated approval in advanced melanoma [18]. Pembrolizumab was 
ultimately compared to ipilimumab in the phase III trial KEY-
NOTE-006. It was administered at 10 mg/kg body weight in 2 dis-
tinct cohorts every 2 and 3  weeks, respectively. The efficacy was 
similar in both of these groups and significantly higher over ipili-
mumab with an estimated 6-month PFS of 46–47% compared to 
27% (HR 0.58; 95% CI 0.46–0.72). The response rates were 34% 
(2-week cycle) and 33% (3-week cycle) in comparison to 12% for 
patients with ipilimumab monotherapy [19]. Regarding safety, 
pembrolizumab was better tolerated than both chemotherapy 
(shown in KEYNOTE-002) and ipilimumab (shown in KEY-
NOTE-006). In 3–7% of patients treatment was discontinued due 
to severe treatment-related adverse events. The most common 
events observed with pembrolizumab are fatigue, diarrhea, rash, 
and pruritus. Immune-related side effects most commonly are 
hyper- and hypothyroidism, colitis, hepatitis, hypophysitis, and 
pneumonitis, although virtually any organ system can be affected 
[19–21].
Nivolumab Monotherapy
Nivolumab is administered intravenously at 3  mg/kg body 
weight every 2 weeks. The phase III study CheckMate 037 evalu-
ated nivolumab in comparison to ICC as second- or later-line 
treatment in patients who were refractory to ipilimumab or BRAFi. 
Confirmed objective responses were reported in 31.7% and 10.6%, 
respectively [22]. These results were further corroborated in previ-
ously untreated patients without a BRAF mutation in the trial 
CheckMate 066, where nivolumab was compared to dacarbazine as 
first-line approach. Patients in the nivolumab arm showed a re-
sponse rate of 40.0% versus 13.9% in the dacarbazine arm. The me-
dian PFS was 5.1 and 2.2 months, respectively (HR 0.43; 95% CI 
0.34–0.56). After 1 year of follow-up, the survival rates were 73% 
and 42%, respectively (HR 0.42; 99.8% CI 0.25–0.73). This survival 
benefit was evident in all pre-specified subgroups including those 
that were defined by expression of the programmed death ligand 1 
(PD-L1), indicating that nivolumab is effective irrespective of 
PD-L1 expression levels [23]. Recently, updated data have been 
presented after an observational time of 18.5 months post therapy. 
After this period of time, the median OS rate had not yet been 
reached in the nivolumab cohort, whereas it was 11.2 months for 
dacarbazine (HR 0.43; 95% CI 0.33–0.57). The median PFS further 
improved to 5.4  months for nivolumab and remained at 
2.2 months with chemotherapy (HR 0.42; 95% CI 0.32–0.53). The 
objective response rates were 42.9% and 14.4%, respectively. The 
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2-year OS for patients who received nivolumab was 68.3% for pa-
tients with  5% PD-L1 expression and 54.2% for those with < 5% 
PD-L1 expression. Treatment-related severe adverse events were 
observed in 10–13% of patients and comprised fatigue, pruritus, 
nausea, diarrhea, and rash. Frequent laboratory abnormalities 
under nivolumab treatment are increased levels of serum lipase 
and alanine aminotransferase [23].
Ipilimumab plus Nivolumab
Several studies provide strong evidence that a primary combi-
nation of CTLA-4 and PD-1/PD-L1 blockade is more effective than 
the respective monotherapies (table  2). High response rates and 
improvement of PFS and OS were already evident in 2 early phase 
trials investigating ipilimumab and nivolumab [24, 25]. However, 
the pivotal study for this drug combination was the 3-armed phase 
III trial CheckMate 067 in which 945 treatment-naïve patients with 
unresectable or metastatic disease were randomized 1: 1:1 to 
nivolumab plus ipilimumab, nivolumab alone, or ipilimumab 
alone, with PFS and OS as co-primary endpoints [26]. Data on the 
first parameter have already been published and revealed a re-
sponse rate of 58% for the combination, 44% for nivolumab alone, 
and 19% for ipilimumab alone. Median PFS was 11.5, 6.9, and 
2.9 months, respectively. The clinical benefit provided by the com-
bination was most evident in patients with PD-L1-negative tumors. 
However, this high antitumor efficacy was accompanied by a high 
frequency of severe immune-related adverse events. In the combi-
nation cohort, virtually all patients experienced at least 1 side ef-
fect, while 57% showed an event of grade 3 or 4. In 39% of all pa-
tients the combination therapy had to be stopped due to side ef-
fects such as diarrhea with colitis or hepatitis with elevated liver 
enzymes. However, no treatment-related death occurred in the 
combination arm of the study, and 85–100% of the severe adverse 
events were managed successfully and fully reversed with the ap-
propriate therapeutic measures [26].
A post-hoc analysis on patients who discontinued ipilimumab 
and nivolumab due to severe adverse events in the phase II trial 
CheckMate 069 was recently presented [27]. After a minimum fol-
low-up of 2  years, median PFS and OS were still not reached in 
randomized patients receiving ipilimumab and nivolumab and 
those who discontinued treatment. Thus, the treatment effects of 
this combination appeared durable with clinical benefit even for 
patients who discontinue therapy early [27].
Ipilimumab plus Pembrolizumab
The combination of ipilimumab and pembrolizumab has been 
assessed in the phase I/II trial KEYNOTE-029 for melanoma and 
renal cell carcinoma. Pembrolizumab was administered at 2 mg/kg 
body weight every 3 weeks with 4 cycles of ipilimumab at 1 mg/kg 
body weight. Recent data after a median follow-up of 10 months 
suggested that this combination was tolerable, as 72% of patients 
received all 4 doses of ipilimumab and no treatment-related deaths 
were observed. Severe immune-related adverse events were re-
ported in 25% of patients. The best overall response rate was 57%. 
However, no phase III trial data are available for pembrolizumab 
and ipilimumab to date [28].
Triple Combination Therapy
Combining tyrosine kinase inhibitors with immune checkpoint 
blockade may result in additional synergism. The triplet combina-
tion of BRAFi, MEKi, and anti-PD-1 showed high antitumor effi-
cacy in preclinical studies. The phase I/II trial KEYNOTE-022 
evaluates the combination of dabrafenib, trametinib and pembroli-
zumab in BRAFV600-mutated melanoma [29]. The dose-finding 
part demonstrated a manageable toxicity profile of the approved 
single-agent doses (dabrafenib 150 mg BID, trametinib 2 mg QID, 
pembrolizumab 2  mg/kg Q3W). 12 out of 13 patients (92.3%) 
showed a decrease from baseline in the size of the target lesions. 
Phase II of this trial is currently further evaluating the safety and 
efficacy of this triplet combination compared to dabrafenib and 
trametinib plus placebo [29].
Conclusion
Patients with a BRAFV600 mutation should receive upfront 
BRAFi and MEKi as first- or second-line therapy. Currently, 2 
combination regimens have been approved by the EMA: dab-
rafenib plus trametinib and vemurafenib plus cobimetinib. They 
have similar antitumor efficacy but a distinct profile of adverse 
events. For BRAF mutation-positive patients, the ideal sequence of 
targeted therapy with kinase inhibitors and immune checkpoint 
blockade is unclear and depends on the clinical course and indi-
vidual patient characteristics.
Pembrolizumab and nivolumab show higher response rates 
compared to ipilimumab and fewer severe immune-related adverse 
events. However, the optimal treatment duration for these agents 
has not been defined yet and long-term data are still lacking. Un-
precedented efficacy was recently yielded with combined CTLA-4 
and PD-1 blockade, although more than half of all treated patients 
experienced an adverse event of grade 3 or 4. However, no treat-
ment-related deaths were recorded and the events could be ade-
quately managed with close clinical monitoring early immuno-
suppression.
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